Literature DB >> 14567027

Natural history of peritoneal carcinomatosis from nongynecologic malignancies.

Olivier Glehen1, Dimitri Osinsky, Annie Claude Beaujard, François Noël Gilly.   

Abstract

Both clinical experience and clinical research show that there is a limited survival, estimated to be approximately 6 months, in patients with peritoneal carcinomatosis from nongynecologic malignancy. Survival is shortest in patients with carcinomatosis from pancreas cancer, and is slightly more prolonged with colon cancer. The short survival is seen when the diagnosis of carcinomatosis is made synchronously with the primary cancer, and also when it is diagnosed in follow-up. A large diagnostic shortcoming is the inability to reliably diagnose carcinomatosis, either with the primary malignancy or with recurrent cancer. The Gilly carcinomatosis staging system has profound prognostic implications in this group of patients. The rapid progression of this disease state and the dependence of benefit upon complete cytoreduction suggests a need for early interventions in selected patients.

Entities:  

Mesh:

Year:  2003        PMID: 14567027     DOI: 10.1016/s1055-3207(03)00044-9

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  26 in total

1.  Establishing of Peritoneal Surface Malignancy Treatment Program: Background in Ukraine, Patient Selection, Staff Schedule, Perioperative Outcomes of First 28 Patients.

Authors:  V I Kopetskyi; K V Kopchak; D O Cheverdiuk; O O Kvasivka; A P Beznosenko; O O Kolesnik; V V Gushchin
Journal:  Indian J Surg Oncol       Date:  2020-03-16

2.  The development of a peritoneal surface malignancy program: a tale of three hospitals.

Authors:  Umut Sarpel; Marcovalerio Melis; Elliot Newman; H Leon Pachter; Russell S Berman
Journal:  J Cancer Educ       Date:  2012-12       Impact factor: 2.037

3.  Hyperthermic intraperitoneal chemotherapy for gastric and colorectal cancer in Mainland China.

Authors:  Tao Suo; Haile Mahteme; Xin-Yu Qin
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

4.  Peritoneal carcinomatosis of colorectal origin.

Authors:  Antonio Macrì; Edoardo Saladino; Vincenzo Bartolo; Vincenzo Adamo; Giuseppe Altavilla; Epifanio Mondello; Giovanni Condemi; Angelo Sinardi; Ciro Famulari
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

5.  Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): two different diseases.

Authors:  M Tonello; G Ortega-Perez; O Alonso-Casado; P Torres-Mesa; G Guiñez; S Gonzalez-Moreno
Journal:  Clin Transl Oncol       Date:  2018-04-17       Impact factor: 3.405

Review 6.  Metastatic Colorectal Cancer to the Peritoneum: Current Treatment Options.

Authors:  Nikolaos Vassos; Pompiliu Piso
Journal:  Curr Treat Options Oncol       Date:  2018-09-01

Review 7.  Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.

Authors:  Simon Binder; Andrew L Lewis; J-Matthias Löhr; Michael Keese
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.

Authors:  Akshat Saxena; Tristan D Yan; David L Morris
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

Review 9.  Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review.

Authors:  Andrew Eisenberger; R Lawrence Whelan; Alfred I Neugut
Journal:  Int J Colorectal Dis       Date:  2008-03-11       Impact factor: 2.571

Review 10.  Multimodality treatment strategies have changed prognosis of peritoneal metastases.

Authors:  Corneliu Lungoci; Aurel Ion Mironiuc; Valentin Muntean; Traian Oniu; Hubert Leebmann; Max Mayr; Pompiliu Piso
Journal:  World J Gastrointest Oncol       Date:  2016-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.